TICKERNERD
Menu
DMACDMACHealthcare · Biotechnology

DMAC Stock Forecast: DiaMedica Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$8.01
+0.25% on the day

The 5 Wall Street analysts covering DiaMedica Therapeutics, Inc. hold a median 12-month price target of $13 — +62.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$438.4M
Ticker Nerd rank
50 / 100
Median analyst target
$13
Analysts covering
5
Revenue$0.0
Operating income−$10.5M
Net income−$10.1M
Free cash flow−$8.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.1%
1M
+22.5%
YTD
+0.6%
1Y
+15.1%
From 52W high
−14.7%
From 52W low
+50.3%
$5.33
$9.39
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DMAC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores DiaMedica Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
69
Accruals
64
Volatility
63
Revisions
59
Momentum
59
Size
55
Issuance
41
Growth
38
Quality
20

Value (69): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Quality (20): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DMAC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DMAC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26DMACHigh $25Median $13Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $11Median $13High $25

The green dot is the last close — the median target sits +62.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026HC Wainwright & Co.ReiteratesBuy$12
14 Nov 2025Cantor FitzgeraldInitiatesOverweight—
14 Nov 2025Cantor FitzgeraldInitiatesOverweight$25
15 Aug 2025HC Wainwright & Co.ReiteratesBuy—
18 July 2025Craig-HallumMaintainsBuy—
18 July 2025HC Wainwright & Co.MaintainsBuy—
18 July 2025Lake StreetMaintainsBuy—
29 May 2025HC Wainwright & Co.ReiteratesBuy—
19 Mar 2025HC Wainwright & Co.MaintainsBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
10 Oct 2024HC Wainwright & Co.ReiteratesBuy—
7 Oct 2024HC Wainwright & Co.InitiatesBuy—
16 Aug 2024OppenheimerReiteratesOutperform—
24 Apr 2024Craig-HallumAssumesBuy$8.00
21 Mar 2024Craig-HallumMaintainsBuy—
21 Mar 2024OppenheimerReiteratesOutperform—
22 June 2023OppenheimerUpgradeOutperform—
7 July 2022Craig-HallumMaintainsBuy—
7 July 2022Lake StreetMaintainsBuy—
7 July 2022OppenheimerDowngradePerform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DMAC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DMAC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, DiaMedica Therapeutics, Inc. returned +15.1% against +16.2% for the S&P 500, dividends included.

DMAC vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Jan 26Apr 26Jul 26Oct 26DMACS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DMAC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

DiaMedica Therapeutics, Inc. (DMAC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.6×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
11.4×

Cheaper than 8% of US stocks

EV / EBITDA
−10.1×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−114.6%

Higher than 12% of US stocks

Return on assets
−64.1%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

DiaMedica Therapeutics, Inc. (DMAC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • DiaMedica Therapeutics, Inc. has a market value of $438.4M and an enterprise value of $395.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$37.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$31.5M.

  • Shares outstanding: 53.9M.

  • Trailing P/E: −11.6×; forward P/E: −10.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • DiaMedica Therapeutics, Inc. employs 35 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

DMAC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DMACDiaMedica Therapeutics, Inc.$438.4M
50
ENTXEntera Bio Ltd.$432.9M
44
EDITEditas Medicine, Inc.$435.8M
80
OVIDOvid Therapeutics, Inc.$436.7M
64
TECXTectonic Therapeutic, Inc.$425.8M
51
RZLTRezolute, Inc.$444.0M
37
SPRYARS Pharmaceuticals, Inc.$450.7M
12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own DiaMedica Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DMAC news & analysis

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results

Business Wire · 30 Sept 2026positive

DiaMedica Therapeutics announced it will host a virtual key opinion leader webinar on October 23, 2026 to discuss fetal growth restriction and the therapeutic rationale for evaluating DM199 (rinvecalinase alfa) as a potential treatment, featuring early Phase 2 FGR results.

Why it matters — The webinar highlights the company's progress in advancing DM199 within its fetal growth restriction program and provides a platform for sharing early Phase 2 clinical data.

DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

Business Wire · 2 Sept 2026neutral

DiaMedica Therapeutics announced that company management will participate in four upcoming investment bank conferences in New York in September 2026, including the Citi Biopharma Back to School Summit and the Cantor Global Healthcare Conference. CEO Rick Pauls is scheduled for a fireside chat as part of the events.

Why it matters — A DiaMedica watcher would care because the conference appearances give management an opportunity to present the company's pipeline to investors and analysts.

Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet

Zacks Investment Research · 26 Aug 2026positive

Zacks Research reports that the average Wall Street price target for DiaMedica Therapeutics implies a potential upside of about 130%. The item notes that while the reliability of this metric is questionable, positive earnings estimate revisions could support upside in the stock.

Why it matters — DMAC watchers would care because analyst price targets and earnings estimate trends offer signals about how the market currently views the stock's potential.

All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy

Zacks Investment Research · 13 Aug 2026positive

Zacks Investment Research upgraded DiaMedica Therapeutics (DMAC) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects that could see the stock move higher.

Why it matters — A DMAC watcher would care because the rating upgrade signals improving analyst sentiment around the company's earnings outlook.

DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Seeking Alpha published the transcript of DiaMedica Therapeutics Inc.'s Q2 2026 earnings call. The excerpt provided includes only the headline and source, with no details on financial results or company commentary.

Why it matters — A DMAC watcher would care because earnings call transcripts are a key source of management commentary and financial detail for the quarter, as published by Seeking Alpha.

FAQ

Frequently asked questions about DMAC stock

What is the DMAC stock price forecast for 2026-2027?

The 5 Wall Street analysts covering DiaMedica Therapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $11 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DMAC stock a buy right now?

Of the 5 analysts covering DiaMedica Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DiaMedica Therapeutics, Inc. 50 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DMAC?

As at 8 Oct 2026, DiaMedica Therapeutics, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (69 of 100).

Will DMAC stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +62.3% from the last close, and Ticker Nerd's factor model ranks DiaMedica Therapeutics, Inc. 50 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DMAC stock forecast for 2030?

No analyst covering DiaMedica Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DMAC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $25 over the next 12 months.

How has DMAC stock performed over the past year?

DiaMedica Therapeutics, Inc. returned +15.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does DiaMedica Therapeutics, Inc. do?

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious vascular and ischemic diseases.

What is the latest news on DMAC?

The most recent item we track (Business Wire, 30 Sept 2026): "DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results". DiaMedica Therapeutics announced it will host a virtual key opinion leader webinar on October 23, 2026 to discuss fetal growth restriction and the therapeutic rationale for evaluating DM199 (rinvecalinase alfa) as a potential treatment, featuring early Phase 2 FGR results.

Company

About DiaMedica Therapeutics, Inc.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious vascular and ischemic diseases. Its current pipeline is centered on DM199, a recombinant form of human tissue kallikrein-1 being studied for acute ischemic stroke, preeclampsia, fetal growth restriction, and other conditions linked to impaired blood flow. The company also advances DM300, a recombinant human ulinastatin candidate in preclinical development for inflammatory disorders. DiaMedica Therapeutics serves the neuroscience, women’s health, renal, and inflammatory disease areas through therapies designed to address significant unmet medical needs. Headquartered in Minneapolis, Minnesota, DiaMedica Therapeutics Inc. operates as a specialized biotech platform focused on recombinant protein-based drug development.

CEO Mr. Dietrich John Pauls MBA · 35 employees · United States · https://www.diamedica.com